What's in Zhejiang Hisun Pharmaceutical Co. Ltd.'s pipeline?

Zhejiang Hisun Pharmaceutical Co. Ltd. has 17 drugs in our index: 5 marketed, 0 filed, 8 in Phase 3, 2 in Phase 2, 2 in Phase 1.

Which companies overlap with Zhejiang Hisun Pharmaceutical Co. Ltd.'s portfolio?

Top competitors by shared drug class: Hoffmann-La Roche, Abbott, Merck Sharp & Dohme LLC, AJU Pharm Co., Ltd., AceLink Therapeutics, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/zhejiang-hisun-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Zhejiang Hisun Pharmaceutical Co. Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Zhejiang Hisun Pharmaceutical Co. Ltd. pipeline: 5 marketed, 0 filed, 8 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 8 Phase 3 2 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Ademetionine 1	Ademetionine 1	marketed	Hepatoprotective agent / Methyl donor	S-adenosylmethionine (SAM) pathway / cellular methylation	Hepatology / Gastroenterology
Ademetionine 2	Ademetionine 2	marketed	Hepatoprotective agent / Methyl donor	S-adenosylmethionine (SAM) / cellular methylation pathways	Hepatology / Gastroenterology
Ademethionine	Ademethionine	marketed			Other
Ademetionine 3	Ademetionine 3	marketed	Methyl donor / Hepatoprotective agent	S-adenosylmethionine (SAM) / Methyltransferase cofactor	Hepatology / Gastroenterology
Polyene Phosphatidyl choline	Polyene Phosphatidyl choline	marketed
Placebe of HS-25 and Atorvastatin	Placebe of HS-25 and Atorvastatin	phase 3	statin	HMG-CoA reductase	Cardiovascular
HS022	HS022	phase 3			Oncology
Vinorelbine Bitartrate	Vinorelbine Bitartrate	phase 3	Vinca alkaloid; microtubule destabilizer	β-tubulin	Oncology
HS628+MTX	HS628+MTX	phase 3	JAK inhibitor (presumed) in combination with antimetabolite		Immunology / Rheumatology
Placebo of HS-25	Placebo of HS-25	phase 3
HS-25	HS-25	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
Actemra +MTX	Actemra +MTX	phase 3	IL-6 receptor antagonist (monoclonal antibody)	IL-6 receptor (IL-6R)	Immunology

Therapeutic area mix

Hepatology / Gastroenterology · 3
Oncology · 2
Cardiovascular · 2
Other · 1
Immunology · 1
Diabetes · 1
Immunology / Rheumatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Hoffmann-La Roche · 2 shared drug classes
Abbott · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
AJU Pharm Co., Ltd. · 1 shared drug class
AceLink Therapeutics, Inc. · 1 shared drug class
Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
Aciex Therapeutics, Inc. · 1 shared drug class
AO GENERIUM · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Zhejiang Hisun Pharmaceutical Co. Ltd.:

Cite this brief

Drug Landscape (2026). Zhejiang Hisun Pharmaceutical Co. Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/zhejiang-hisun-pharmaceutical-co-ltd. Accessed 2026-05-17.